Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 9/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25939486 | 0.99 | DHODH (0.51) | DHODHHRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL25939483 | 0.91 | DHODH (0.50) | DHODHPARP1FAAHAVPR1BMGLL | |
| SCHEMBL25939476 | 0.84 | DHODH (0.48) | DHODHHRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL15987179 | 0.84 | DHODH (0.52) | DHODHHRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL15973464 | 0.83 | DHODH (0.51) | DHODHHRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL15973385 | 0.82 | DHODH (0.52) | DHODHHRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL25939447 | 0.81 | DHODH (0.49) | DHODH | |
| SCHEMBL21905243 | 0.77 | DHODH (0.83) | DHODH | |
| SCHEMBL25939496 | 0.77 | DHODH (0.49) | DHODHPARP1SLC2A1FAAHMGLL | |
| SCHEMBL21905255 | 0.77 | DHODH (0.81) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | BRDT, BRPF3, BRD4 | DHODH 441/4885HRH3 810/4885CYP2D6 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.